Rapid Readouts

The Phase 3 PAPILLON study evaluated first-line amivantamab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer with EGFR Exon 20 insertion mutations. The amivantamab-chemotherapy group achieved the longest median overall survival reported to date in this population compared to chemotherapy alone. After adjusting for the high rate of crossover to second-line amivantamab among patients initially assigned to chemotherapy, the combination treatment demonstrated a statistically significant overall survival benefit.

Roy S. Herbst, MD, PhD, reviews the exploratory 8-year overall survival landmark update from the phase 3 ADAURA trial of adjuvant osimertinib versus placebo in patients with resected EGFR-mutated stage IB to IIIA non-small cell lung cancer, presented at the 2026 World Conference on Lung Cancer.

The EXCALIBER-RRMM clinical trial evaluated a combination therapy of iberdomide, daratumumab, and dexamethasone against daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma. The trial demonstrated that adding the cereblon E3 ligase modulator iberdomide significantly improved minimal residual disease-negative complete response rates across diverse patient subgroups while maintaining a predictable and manageable safety profile. Based on these outcomes, the regulatory authority granted accelerated approval for this treatment combination as a new standard of care for patients experiencing early relapse.

Julia Rotow, MD, of Dana-Farber Cancer Institute, reviews primary results of the phase 3 DESTINY-Lung04 trial showing first-line trastuzumab deruxtecan improved progression-free survival and response rate compared with pembrolizumab plus platinum chemotherapy and pemetrexed in patients with metastatic HER2-mutant non-small cell lung cancer.

Yi-Long Wu, MD, PhD, of the Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, presents updated overall survival and safety findings from Stage 1 of the phase 3 PRESERVE-003 trial of gotistobart vs docetaxel in patients with metastatic squamous non–small cell lung cancer whose disease progressed after chemotherapy and PD-1 or PD-L1 inhibitor therapy.

Rapid readout: PEAK trial shows besiclastinib plus sunitinib boosts second-line GIST PFS and response, with manageable safety.

Dr. Neeta Somaiah discusses PEAK trial results showing that adding bezuclastinib to sunitinib nearly doubled median progression-free survival (16.5 vs 9.2 months) and improved overall response rate versus sunitinib alone in second-line, imatinib-resistant gastrointestinal stromal tumors.

Jonathan Strosberg, MD, of Moffitt Cancer Center, discusses phase 3 COMPETE trial results showing ¹⁷⁷Lu-edotreotide improved progression-free survival, response rate, and safety compared with everolimus in patients with advanced gastroenteropancreatic neuroendocrine tumors.

Pedro Barata, MD, highlights a clinical and economic analysis in mCRPC demonstrating that while Lu-PSMA offers superior disease control, cabazitaxel provides comparable overall survival at a substantially lower cost.

The COPERNICUS study evaluates the safety and patient characteristics of a subcutaneous treatment regimen combined with targeted therapies and proactive side-effect management for advanced lung cancer.

Amir T. Fathi, MD, presents a multicenter retrospective cohort study demonstrating that intensive chemotherapy plus quizartinib was associated with superior 1-year overall survival (93% vs 78%; adjusted HR, 0.19) and event-free survival compared with intensive chemotherapy plus midostaurin in patients with newly diagnosed FLT3-ITD–mutated acute myeloid leukemia.

Wojciech Jurczak, MD, PhD, reviews EHA 2026 data supporting continuous zanubrutinib as a frontline treatment option for chronic lymphocytic leukemia, including findings from a matching-adjusted indirect comparison with ibrutinib.

Charu Aggarwal, MD, MPH, discusses planned interim results from the phase 2b TRITON trial evaluating tremelimumab plus durvalumab and chemotherapy versus pembrolizumab plus chemotherapy in patients with previously untreated metastatic non–small cell lung cancer harboring STK11, KEAP1, and/or KRAS mutations.

Ibrahim Aldoss, MD, discusses updated phase 1 results from the SNDX-5613-0708 study of revumenib plus intensive chemotherapy in patients with newly diagnosed AML harboring KMT2A, NPM1, or NUP98 alterations.

Rapid readout: New-onset AFib in CLL links to higher stroke, bleeding, heart failure, and care use; real-world data hints zanubrutinib lowers risk.

This presentation shows that the next-generation BTK inhibitor zanubrutinib demonstrates increasingly durable long-term survival and progression-free benefits compared with ibrutinib and acalabrutinib in previously untreated chronic lymphocytic leukemia, supporting its use as a preferred frontline therapy when direct comparative trial data are unavailable.

Ryan Jacobs, MD, discusses real-world data showing that first-line zanubrutinib was associated with longer time to next treatment and improved overall survival vs acalabrutinib in patients with CLL/SLL.

Seven-year data show lorlatinib keeps ALK+ lung cancer controlled, with durable brain protection, stable safety, and clues to early resistance.

Daniel A. Ermann, MD, reviews a large Medicare Fee-for-Service analysis showing zanubrutinib was associated with longer real-world treatment duration, time to next treatment, and overall survival vs acalabrutinib and ibrutinib in older patients with first-line CLL.

Michael Fradley, MD, discusses real-world data linking atrial fibrillation with increased cardiovascular and health care utilization burden in CLL/SLL, along with exploratory findings for first-line BTK inhibitors.

Jiong Wu, MD, PhD, discusses phase 3 PANKU-Breast02 findings showing that izalontamab brengitecan improved progression-free and overall survival vs chemotherapy in patients with previously treated unresectable locally advanced or metastatic triple-negative breast cancer.

Nilanjan Ghosh, MD, reviews phase 3 data showing that tafasitamab plus lenalidomide and R-CHOP improved progression-free survival vs R-CHOP alone in patients with newly diagnosed high-risk DLBCL.

Peter Voorhees, MD, presents phase 3 MonumenTAL-3 data supporting talquetamab plus daratumumab, with or without pomalidomide, as a potential new standard for early relapsed/refractory multiple myeloma.

This presentation presents the first global clinical trial results evaluating the investigational bispecific antibody pumitamig combined with chemotherapy as a first-line treatment for advanced non-small cell lung cancer.

Phase II data show Silevertinib boosts responses and brain control in treatment‑naive EGFR non‑classical NSCLC, with manageable rash/diarrhea.

This presentation details results from the global Phase 3 FIGHT-302 trial, which evaluated pemigatinib compared to standard chemotherapy for patients with advanced or metastatic cholangiocarcinoma containing specific genetic rearrangements.

This phase 1b analysis from the ELEVATE study evaluated the combination of elacestrant and capivasertib in patients with ER-positive, HER2-negative advanced breast cancer whose tumors harbored alterations in the PI3K/AKT pathway. The combination demonstrated a manageable safety profile with no new safety concerns and showed encouraging antitumor activity, including durable disease control across a heavily pretreated population. These findings support further investigation of this all-oral regimen as a strategy to simultaneously target endocrine resistance and PI3K/AKT pathway–driven disease.

David M. Waterhouse, MD, MPH, reviews real-world claims data suggesting substantial underdiagnosis of Lambert-Eaton myasthenic syndrome among patients with small cell lung cancer and the need for improved recognition in oncology practice.

Jae Park, MD, discusses findings from the FELIX study showing that obecabtagene autoleucel demonstrated clinically meaningful activity and a manageable safety profile in adults with relapsed/refractory B-cell acute lymphoblastic leukemia, including those with extramedullary disease at lymphodepletion.

Timothy Cloughesy, MD, presents updated INDIGO data showing that vorasidenib provides durable progression-free survival benefit and delays subsequent intervention in patients with IDH-mutant grade 2 glioma.